Temasek backed Molbio Diagnostics files for IPO at ₹12,000-cr valuation

Temasek's subsidiary, and Motilal Oswal-backed Molbio Diagnostics, has filed IPO papers with SEBI to raise ₹200-crore via fresh issue and the remaining via OFS. Existing shareholders, including promoters and investors of the firm valued at ₹12,490-crore, will be selling 1.25 crore equity shares via OFS. The funds will be used to build new R&D, office facilities and upgrade manufacturing.